In Brief: Neopath
This article was originally published in The Gray Sheet
Executive Summary
Neopath: Investigating complementing its AutoPap 300 automated Pap smear analyzer system with Cambridge, Massachusetts-based CompuCyte Corporation's Pathfinder cytology system, which it has purchased for $5 mil. in cash and stock. The Pathfinder, which consists of a microprocessor-controlled microscope capable of recording data on screened areas, will continue to be sold as a stand-alone product while NeoPath investigates using it to "guide the cytotechnologist to suspicious cells identified by the AutoPap," the firm says in a release...